Enhanced symptom management for EGFR-mutated lung cancer on amivantamab
Part of Cancer, Heart & circulation, Lungs & breathing clinical trials.
This trial tests whether extra care for skin and infusion reactions can help people with EGFR-mutated advanced lung cancer better tolerate treatment with amivantamab-based therapies. It compares two approaches in three different patient groups.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have advanced or metastatic EGFR-mutated non-small cell lung cancer (stage IIIB, IIIC, or IV).
- You must be in fairly good physical condition (able to care for yourself and do daily activities).
- You must be willing to follow a special plan to prevent and manage skin problems and infusion reactions during treatment.
- For some groups: you must have either a specific EGFR mutation (exon 19 deletion or L858R) or an EGFR exon 20 insertion mutation, and have not had prior treatment for advanced disease (or have had only one prior targeted therapy, depending on the group).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two drugs for people with a specific type of lung cancer that has spread to the lining of the brain and spinal cord. The treatment aims to target the cancer cells and may help improve symptoms and survival.
This study looks at how well a treatment called amivantamab works in people with a specific type of advanced lung cancer (EGFR-mutated non-small cell lung cancer). It aims to track real-world outcomes in patients who are starting amivantamab for the first time.
This trial tests two treatment combinations for people with a specific type of advanced lung cancer that has an EGFR mutation. One group gets amivantamab plus lazertinib, and the other gets amivantamab plus chemotherapy. The goal is to see which combo works better.
This trial tests whether the drug amivantamab combined with a single chemotherapy drug can help people with advanced non-small cell lung cancer that has a specific EGFR gene mutation (exon20 insertion). It is for people who cannot safely receive standard platinum-based chemotherapy.
This trial tests a combination of two targeted therapies (amivantamab and lazertinib) or amivantamab with chemotherapy for people with advanced lung cancer that has a specific EGFR mutation. It aims to see if these treatments work better together than current options.
This study follows patients with advanced lung cancer (a type called non-small cell lung cancer) who are receiving a combination of chemotherapy and a drug called amivantamab. Researchers want to understand how well this treatment works and track your health outcomes over time.
Hear when a new NSCLC (Advanced Non-small Cell Lung Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.